» Articles » PMID: 16703880

Desmoid-type Fibromatoses Involving the Brachial Plexus: Treatment Options and Assessment of C-KIT Mutational Status

Overview
Journal J Neurosurg
Specialty Neurosurgery
Date 2006 May 18
PMID 16703880
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Object: Desmoid-type fibromatoses are a locally invasive soft-tissue lesion that is most commonly encountered in abdominal sites. The tumor also affects head and neck areas, particularly the supraclavicular region, where it may encase and distort the brachial plexus and compromise neurovascular structures. Neurosurgeons may be called on to treat desmoid-type fibromatoses in these sites. The authors describe their experience in treating four patients with desmoid-type fibromatoses involving the brachial plexus and report the results of immunohistochemical analysis of the tumors.

Methods: Gross-total excision with nerve sparing was the first-line therapy of choice, although the surgery was challenging. Intraoperative identification of the site of tumor origin from musculoaponeurotic tissues by the neurosurgeon was necessary in two of the four cases to achieve a correct frozen section or final pathological diagnosis. Immunostaining for c-KIT (CD117) was undertaken in all cases in light of a previous report of positive CD117 immunoreactivity in abdominal desmoid-type fibromatoses. All four tumors manifested weak focal immunostaining for c-KIT. One of the patients was given adjuvant imatinib mesylate therapy, with limited success. Subsequent polymerase chain reaction testing revealed that three of the four tumors manifested a single base pair change in exon 10 of the c-KIT gene (A to C in two cases and A to G in one case). There was local recurrence in three patients, despite gross-total excision. With the combination of surgery and radiation therapy, local disease control was achieved in three of the four patients.

Conclusions: This represents the first report of c-KIT sequencing in desmoid-type fibromatoses and suggests a possible biological basis for continuing to explore the use of adjuvant imatinib mesylate therapy.

Citing Articles

Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.

Ivanov M, Laktionov K, Breder V, Chernenko P, Novikova E, Telysheva E J Transl Med. 2017; 15(1):22.

PMID: 28137276 PMC: 5282851. DOI: 10.1186/s12967-017-1125-8.


Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.

Masago K, Fujita S, Muraki M, Hata A, Okuda C, Otsuka K BMC Cancer. 2015; 15:908.

PMID: 26572169 PMC: 4647703. DOI: 10.1186/s12885-015-1925-2.


Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology.

Dufresne A, Alberti L, Brahmi M, Kabani S, Philippon H, Perol D BMC Cancer. 2014; 14:632.

PMID: 25174682 PMC: 4161827. DOI: 10.1186/1471-2407-14-632.


Desmoid tumour of the brachial plexus.

Juliette O, Florentius K, Francis N, Macharia B, Neema M Case Rep Surg. 2013; 2013:575982.

PMID: 23841010 PMC: 3694380. DOI: 10.1155/2013/575982.


Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.

Dufresne A, Bertucci F, Penel N, Le Cesne A, Bui B, Tubiana-Hulin M Br J Cancer. 2010; 103(4):482-5.

PMID: 20664593 PMC: 2939782. DOI: 10.1038/sj.bjc.6605783.